Melphalan flufenamide (melflufen) and Dexamethasone re-induction in Daratumumab-refractory Multiple Myeloma as an Adjunct to Continued Daratumumab (MERMAID)
Latest Information Update: 28 Dec 2021
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MERMAID
- 22 Dec 2021 Status has been changed to discontinued.
- 29 Jul 2021 Status changed from recruiting to suspended due to the detrimental effect on overall survival of patients in the OCEAN trial, according to a Food and Drug Administration media release
- 18 May 2021 New trial record